PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer

jotaylor

METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline

continue reading